Get the Stockscreener App
3.45
4.17%
-0.15
Pre-market:
3.34
-0.11
-3.19%
Amylyx Pharmaceuticals Inc stock is traded at $3.45, with a volume of 3.19M.
It is down -4.17% in the last 24 hours and down -14.81% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
See More
Previous Close:
$3.60
Open:
$3.43
24h Volume:
3.19M
Relative Volume:
2.52
Market Cap:
$295.63M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
4.9286
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
+10.22%
1M Performance:
-14.81%
6M Performance:
+70.79%
1Y Performance:
-77.02%
1-Day Range:
$3.11
$3.48
1-Week Range:
$3.11
$3.665
52-Week Range:
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
3.45 | 295.63M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
FDA clears Amylyx to resume ALS drug trial in North America - Investing.com
FDA lifts clinical hold on Amylyx’s Phase I ALS trial - Yahoo Finance
FDA lifts clinical hold on Amylyx ALS drug study - MSN
Amylyx Says FDA Lifts Clinical Hold on ALS-Drug Trial - MarketWatch
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire
Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33 - MarketBeat
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - AccessWire
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - AccessWire
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock - BioSpace
Amylyx stock dips after pricing $60M stock offering - MSN
Amylyx Pharmaceuticals Announces Common Stock Offering to Fuel Commercialization Plans - StockTitan
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
Amylyx Pharmaceuticals co-CEO Justin Klee sells $30,201 in stock By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - AccessWire
Justin B. Klee Sells 7,471 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock - MarketBeat
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 - Investing.com
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
ALS drugs from Denali, Calico come up short, marking more failures for Healey trial - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - AccessWire
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer - citybiz
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
AMYLYX PHARMACEUTICALS 48 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Amylyx - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - AccessWire
Amylyx and Gubra collaborate to develop long-acting GLP-1 receptor antagonist - BioWorld Online
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Up 8.3% in December - MarketBeat
Amylyx inks deal with Gubra for diabetes treatment By Investing.com - Investing.com Nigeria
Amylyx inks deal with Gubra for diabetes treatment - Investing.com India
Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
Gubra A/S Announces New Collaboration with Amylyx Pharmaceuticals, Inc. to Develop a Novel Long-Acting GLP-1 Receptor Antagonist - Marketscreener.com
Amylyx Partners with Gubra for GLP-1 Antagonist - TipRanks
Gubra in collaboration with Amylyx to develop long-acting GLP-1 antagonists - Marketscreener.com
Jane Street Group LLC Sells 146,934 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - AccessWire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by XTX Topco Ltd - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $7.33 Consensus Target Price from Brokerages - MarketBeat
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding - Simply Wall St
Fmr LLC Grows Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Drops By 5.2% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - AccessWire
Progressive Supranuclear Palsy Market Statistics Expected - openPR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - AccessWire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Amylyx stock receives Buy rating from H.C. Wainwright, set for Phase 3 trial significance - Investing.com
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):